Evolution of the American Concept of Schizoaffective PsychosisMaj M.
Psychiatric Clinic, First Medical School, University of Naples, Italy; Department of Psychiatry, University of Umeå, Sweden
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
A brief survey is given of the evolution of the concept of schizoaffective psychosis in the United States. The following phases are singled out: a first, ‘prehistoricaΓ, one including description of’mixed’ psychotic syndromes regarded as subtypes of manic-depressive psychosis; a second, which covers the subsequent 30 years, in which the concept of schizoaffective psychosis is gradually included under the heading of schizophrenia, in accordance with the broad Bleulerian concept of this illness prevailing in those years; a third one, in which, under the influence of a number of factors, schizoaffective psychosis is shifted from the schizophrenic to the affective area, and even good-prognosis schizophrenia and DSM III schizophreniform disorder (a syndrome characterized by the same clinical picture of schizophrenia, but which lasts less than 6 months) are regarded as variants of affective illness. It is emphasized that the history of the evolution of the American concept of schizoaffective psychosis is, indeed, the history of the vicissitudes of the American conceptions of schizophrenia and manic-depressive psychosis.
© 1984 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.